awmsg logo



imatinib (Glivec®)


Reference No. 2014

Publication date:
04/12/2013


Appraisal information

imatinib (Glivec®) 100 mg film-coated tablet
imatinib (Glivec®) 400 mg film-coated tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 02/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, imatinib (Glivec®) cannot be endorsed for use within NHS Wales for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
Statement of Advice (SOA)
Download